Registration No. 333-237820
(To prospectus dated May 14, 2020)
Pre-funded warrants to purchase 3,511,111 shares of common stock
| | Per share | | | Per pre-funded warrant | | | Total | |
Public offering price | | | $4.50 | | | $4.49 | | | $99,964,896.89 |
Underwriting discounts and commissions(1) | | | $0.27 | | | $0.27 | | | $6,000,000.48 |
Proceeds to BioCryst, before expenses | | | $4.23 | | | $4.22 | | | $93,964,896.41 |
(1) | We have agreed to reimburse the underwriters for certain FINRA-related expenses. See “Underwriting.” |
J.P. Morgan | | | Piper Sandler |
H.C. Wainwright & Co. | | | JMP Securities |